Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery

Rhea-AI Filing Summary

WITTE OWEN N. reported acquisition or exercise transactions in this Form 4 filing.

Allogene Therapeutics director Owen N. Witte received a grant of 95,400 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date.

Witte has elected to defer receipt of the underlying common shares until the earlier of 30 days after his separation from continuous service with the company or a change in control of Allogene, in line with the company’s Non-Employee Director Compensation Policy.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WITTE OWEN N.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	95,400	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 95,400 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 95,400 units Shares per RSU: 1 share per unit Vesting schedule: 2 equal semi-annual tranches over 1 year +3 more

6 metrics

RSUs granted 95,400 units Restricted Stock Units awarded to director Owen N. Witte

Shares per RSU 1 share per unit Each RSU represents one share of Allogene common stock

Vesting schedule 2 equal semi-annual tranches over 1 year RSUs vest over one-year period from grant date

Total RSUs after grant 95,400 units Total RSUs beneficially owned following the reported transaction

Deferral trigger 1 30 days after separation Share delivery deferred until 30 days following separation from continuous service

Deferral trigger 2 Change in control Alternative trigger for RSU share delivery under company policy

Key Terms

Restricted Stock Unit, contingent right, Non-Employee Director Compensation Policy, change in control

4 terms

Restricted Stock Unit financial

"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company Common Stock."

Non-Employee Director Compensation Policy financial

"pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days..."

change in control financial

"until earlier of (i) 30 days following separation... and (ii) a change in control of the Company."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:30 PM Accepted by SEC EDGAR 06/23/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WITTE OWEN N.

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/18/2026		A		95,400		(1)	(1)	Common Stock	95,400	$0	95,400	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Allogene Therapeutics (ALLO) report for Owen N. Witte?

Allogene Therapeutics reported that director Owen N. Witte received a grant of 95,400 Restricted Stock Units. These RSUs are a form of equity compensation and each unit represents a contingent right to receive one share of Allogene common stock in the future.

How do the 95,400 RSUs granted to Owen N. Witte at Allogene (ALLO) vest?

The 95,400 RSUs granted to Owen N. Witte vest in two equal semi-annual installments over one year from the grant date. This means half vest after six months and the remaining half after twelve months, subject to his continued service with Allogene.

What does Owen N. Witte’s deferral election mean for his Allogene (ALLO) RSUs?

Owen N. Witte elected to defer receipt of Allogene common stock underlying his RSUs. He will receive the shares at the earlier of 30 days after separating from continuous service with the company or upon a change in control of Allogene Therapeutics, per company policy.

Does the Allogene (ALLO) Form 4 show Owen N. Witte buying or selling shares?

The Form 4 shows an equity award, not an open-market trade. Owen N. Witte received 95,400 Restricted Stock Units as a grant, classified as an acquisition of derivative securities rather than a purchase or sale of already outstanding Allogene common shares.

How many Allogene (ALLO) RSUs does Owen N. Witte hold after this grant?

After this reported transaction, Owen N. Witte holds 95,400 Restricted Stock Units linked to Allogene common stock. This figure reflects the total RSUs reported following the grant and will convert into the same number of shares when delivered, subject to vesting and deferral terms.